Riskpilot← Back to searchSign inGet full accessRYFYLKE APOTEK AS
ASActiveOrg 994314335Vikevågveien 125, 4150 RennesøyRetail sale of pharmaceutical products · NACE 4773Est. 200911 employees
Revenue 2024
NOK 26,1M
+9% vs 2023
EBITDA margin
5.6%
+31% vs 2023
Equity ratio
47.4%
Financial strength
Net profit 2024
NOK 1,4M
+33% vs 2023
| Revenue | NOK 26,1M | +9% |
| EBITDA | NOK 1,5M | +31% |
| Net profit | NOK 1,4M | +33% |
| Total assets | NOK 7,7M | -12% |
| Equity | NOK 3,7M | +44% |
| Employees | 11 | — |
Legal name
RYFYLKE APOTEK AS
Org number
994314335
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
13. juli 2009
Share capital
NOK 1 700 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Salg av medisiner, medisinsk utstyr og andre produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretagender.
Address
Vikevågveien 125, 4150 Rennesøy
Phone
+4751720990
Email
ryfylke@dittapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 21 194 | 21 111 | 21 102 | 23 891 | 26 064 |
| Staff expenses | −2 921 | −3 835 | −3 733 | −4 140 | −4 376 |
| EBITDA | 1 300 | 236 | 618 | 1 117 | 1 460 |
| Depreciation & amort. | −35 | −27 | −30 | −28 | −30 |
| EBIT | 1 264 | 209 | 588 | 1 090 | 1 430 |
| Net financials | 4 | −0 | 167 | 212 | 303 |
| Profit before tax | 1 268 | 209 | 755 | 1 301 | 1 733 |
| Tax | 279 | 46 | 166 | 286 | 382 |
| Net profit | 989 | 163 | 589 | 1 015 | 1 352 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 189 | 7 915 | 9 463 | 8 814 | 7 714 |
| Equity | 2 269 | 2 285 | 2 287 | 2 548 | 3 659 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 920 | 5 630 | 7 176 | 6 266 | 4 055 |
| Total debt | 3 920 | 5 630 | 7 176 | 6 266 | 4 055 |
EBITDA margin
5.6%
This company
15.8%
Market median
-65% vs market
20202024
Equity ratio
47.4%
This company
38.2%
Market median
+24% vs market
20202024
Return on equity
36.9%
This company
18.4%
Market median
+101% vs market
20202024
Net profit margin
5.2%
This company
8.1%
Market median
-36% vs market
20202024
Asset turnover
3.38×
This company
1.12×
Market median
+202% vs market
20202024
Debt / equity
1.11×
This company
0.62×
Market median
-79% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CS Chief Executive Officer | Chief Executive Officer | 2017 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2015 | |
| Board of Directors | 2015 | |
| Board of Directors | 2015 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kjosavik Gruppen As
RYFYLKE APOTEK AS Board members of RYFYLKE APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Caroline Skjørvestad Kloster | Chief Executive Officer | 0 companies |
| Dag Gunnstein Kjosavik | Chairman | 0 companies |
| Gunnstein Kjosavik | Board of Directors | 0 companies |
| Ståle Klippen | Board of Directors | 0 companies |